AARDEX Partners with Mevia to Test Evolution of Real-Time Adherence Technology
AARDEX Partners with Mevia to Test Evolution of Real-Time Adherence Technology
Integration of AARDEX MEMS AS and MEMS Mobile technology with Mevia's Medose dispenser offers opportunity to pilot next stage in reusable and real-time adherence solutions.
Liege, Belgium- June 8th, 2023: Adherence specialist AARDEX Group is proud to announce its partnership with Mevia, a developer of exciting new reusable medication adherence hardware with 4G connectivity.
The partnership is an opportunity to test and pilot Mevia's reusable hardware, which transmits when a dose is extracted in real-time, with AARDEX's market-leading MEMS AS and MEMS Mobile technology.
Bernard Vrijens, Chief Executive Officer & Scientific Lead, AARDEX Group, said: "AARDEX Group is continuously looking for new partnerships to enhance the quality of real-time medication adherence data. We look forward to testing Mevia's reusable hardware, which is a new evolution in dosing monitoring."
Trusted by the world's leading pharmaceutical firms, MEMS AS medication adherence software is the gold standard for measuring medication adherence in clinical trials, while MEMS Mobile provides a user-friendly app helping participants to stay on track.
Mepill and Medose detect when a trace is broken and transfers real-time data on the exact dose taken. The user is updated through an e-ink display or a LED light on the device. Fully reusable, the cavities of the dose packages can be filled in automated machines by the pharmacy, Contract Manufacturing Organization (CMO), or manually.
Jesper Hassel, Chief Executive Officer, and Co-Founder, Mevia, said: "We look forward to working together with AARDEX Group to be able to offer a holistic solution to pharmaceutical firms and reach a broader customer base. MEMS AS software and our unique hardware will be a great combined offering."
To find out more about AARDEX Group's solutions, visit aardexgroup.com.
-ENDS-
About AARDEX Group
At AARDEX Group, we believe in the power of digital solutions to revolutionize the way we measure and manage medication adherence. We're not just talking the talk; we're walking the walk as the global leader in this space. Our cutting-edge technology, MEMS® Adherence Software (MEMS AS®), is the cornerstone of a comprehensive ecosystem designed to deliver accurate, data-driven adherence analytics across all forms of drug administration. But we don't stop there. Our team is dedicated to continuously innovating and pushing the boundaries of what's possible in the world of clinical trials. Our mission is simple yet ambitious: to empower patients and revolutionize the way we approach medication adherence in clinical trials through the use of data and technology. At AARDEX, we're not just making a difference; we're leading the charge. www.aardexgroup.com
About Mevia
Mevia is an innovative partner to life science companies in solving the problem of medication non-adherence through reliable, customized, and user-friendly end-to-end solutions. Mevias cloud-based software and hardware focuses on simplicity for all of its stakeholders, offering either complete solutions or combining our offering with partners to enable a smooth process for the end users. Mevia's unique patented hardware solutions enable us to measure adherence to medication in the simplest way possible for the patient; all they need to do is take their dose; no need for APPs, Bluetooth, or Wi-Fi. For more information, visit Mevias website at www.mevia.se